Retinoids and topical acids most often fail through early discontinuation, not lack of efficacy. Dryness, peeling, erythema and stinging peak in the first weeks, when patients decide whether to continue. Controlled-release nanovesicle vehicles flatten the early concentration spike and support the barrier, which addresses the leading cause of drop-off without changing the active.
The adherence problem nobody prescribes for
Topical retinoids are a cornerstone of acne management in current guidelines,[1] and the backbone of photoageing treatment.[2] Azelaic acid and alpha-hydroxy acids fill neighbouring roles. All of them share a weakness that has nothing to do with pharmacology: patients stop using them.
Guideline authors and reviewers keep naming the same cause. Local irritation (dryness, scaling, erythema, burning, stinging) is the most common adverse effect of topical retinoids, and it is worst in the first weeks.[1][2] Azelaic acid has a similar pattern of early burning and itching.[3] Clinical benefit typically takes 8–12 weeks to appear, so many patients stop while they are getting the side effects and none of the reward.
Irritation follows the concentration peak
A conventional cream, gel or solution releases most of its free active in the first minutes to hours after application. That produces a high early concentration at the surface and in the upper epidermis, and irritation tracks that peak more closely than the total dose. The active then declines quickly through absorption, oxidation, rub-off and washing.
A controlled-release vehicle aims for a different shape: a lower peak and a longer time in the effective range. The same molecule spends more of the day where it works and less of the first hour above the irritation threshold.
How a nanovesicle vehicle produces that profile
Cetosome® nanovesicles hold actives in two places. Lipophilic molecules such as retinoids partition into the cetylated lamellae, and polar molecules associate with the solvent-rich mantle.[6] After application, the vesicles move through the stratum corneum and break into smaller penetration units, releasing cargo in phases rather than all at once.[6] The lipid chemistry is lamellar and barrier-compatible. The patent describes delivery without permanent disruption of barrier function, which matters because a damaged barrier both causes and amplifies irritation.[7]
Retinoids gain a second benefit: shielding from oxidation. Retinol and retinaldehyde degrade on exposure to light and air, and a lipid shell reduces that exposure both in the pack and on the skin.
What the cetosome vehicle data show
Published controlled clinical data on cetosomal vehicles currently come from topical minoxidil, where conventional vehicles are known to irritate:
Study | Design | n | Tolerability finding |
|---|---|---|---|
Sattur et al., 2023[4] | Randomised, open-label; cetosomal vs alcohol-based 5% minoxidil, 16 weeks | 80 enrolled / 40 analysed | AEs in 9% (cetosomal) vs 41% (alcohol-based), p = 0.02; no discontinuations |
Kerure et al., 2023[5] | Retrospective, 66 centres, 16 weeks | 261 | 1 treatment-related AE (0.3%); tolerability rated "excellent" by 64–69% |
How to read this evidence: both studies are small or retrospective, and both involve authors affiliated with the product's marketing company. Efficacy differences in the randomised study were not statistically significant. They give a consistent tolerability signal for the vehicle. They do not prove that cetosomal retinoids or acids outperform conventional vehicles, and dedicated trials are needed.
A practical framework for clinicians
- Ask how patients stopped previous treatments. "It stung" or "I peeled" usually points to the vehicle, not the molecule.
- Match vehicle to barrier state. Rosacea, atopic tendency and post-procedure skin call for a vehicle that releases slowly and supports the barrier.
- Separate titration from formulation. Short-contact and alternate-night schedules reduce exposure over time. Controlled-release vehicles reduce the peak within each application. The two work together.
- Keep the counselling. No vehicle replaces sun protection, moisturiser use and setting expectations about the timeline.
The bottom line
Retinoids and acids already work as molecules. When they fail in practice, it is usually because patients stop in the first weeks, and vehicle engineering is the most direct way to address that.
Frequently asked
Why do patients stop using retinoids?
Mainly because of local irritation: dryness, peeling, erythema, burning and itching, often called retinoid dermatitis. It is most intense during the first weeks of treatment, before clinical benefit is visible, so adherence suffers most early on.
Does controlled release reduce retinoid irritation?
Controlled-release and encapsulated vehicles lower the peak concentration of free retinoid at the skin surface and in the epidermis, and that peak is closely linked to irritation. Formulation advances of this kind are among the main strategies to improve retinoid tolerability.
Is there clinical evidence that cetosomal vehicles are better tolerated?
In a randomised, open-label comparison of 5% minoxidil, 9% of patients on the cetosomal formulation reported adverse events versus 41% on an alcohol-based solution (p = 0.02). A 261-patient retrospective study reported 1 treatment-related adverse event (0.3%). These are vehicle-level signals from small, industry-affiliated studies in a different indication.
References
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74(5):945–973.e33. 2016.DOI 10.1016/j.jaad.2015.12.037
- Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clinical Interventions in Aging 1(4):327–348. 2006.DOI 10.2147/ciia.2006.1.4.327
- Fitton A, Goa KL. Azelaic Acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41(5):780–798. 1991.DOI 10.2165/00003495-199141050-00007
- Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
- Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).
- Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
- Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
Methodology
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Conflict of interest & scope
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.